Peptides derived from proteolytic processing of the ␤-amyloid precursor protein (APP), including the amyloid-␤ peptide (A␤), play a critical role in the pathogenesis of Alzheimer's dementia. We report that transgenic mice overexpressing APP and A␤ have a profound attenuation in the increase in neocortical blood flow elicited by somatosensory activation. The impairment is highly correlated with brain A␤ concentration and is reproduced in normal mice by topical neocortical application of exogenous A␤1-40 but not A␤1-42. Overexpression of M146L mutant presenilin-1 in APP mice enhances the production of A␤1-42 severalfold, but it does not produce a commensurate attenuation of the hyperemic response. APP and A␤ overexpression do not diminish the intensity of neural activation, as reflected by the increase in somatosensory cortex glucose usage. Thus, A␤-induced alterations in functional hyperemia produce a potentially deleterious mismatch between substrate delivery and energy demands imposed by neural activity.
T
he amyloid precursor protein is closely linked to the pathogenesis of Alzheimer's dementia (AD; refs. 1 and 2). Mutations in all three early onset familial AD genes, the amyloid precursor protein (APP), presenilin-1 (PS1), and 2 (PS2), cause elevation of APP-derived A␤ peptides that accumulate in the brain parenchyma and blood vessels (3) (4) (5) . These observations, collectively, have led to the hypothesis that A␤ peptides are intimately involved in the pathogenesis of AD. Furthermore, transgenic mice overexpressing APP have increased levels of A␤ in brain, and transgenic lines expressing high levels of mutant APP develop some of the pathological and behavioral hallmarks of AD (6) .
The mechanisms by which A␤ contributes to neuronal dysfunction and neurodegeneration in AD have not been elucidated. Although most studies have focused on the effects of A␤ on neurons, recent evidence suggests that A␤ has profound effects on cerebral blood vessels as well (7) (8) (9) (10) . Patients with AD have morphological alterations of the cerebral vasculature and reduced cerebral blood flow (CBF), and mice overexpressing APP have a marked impairment in the response of cerebral blood vessels to exogenous vasoactive agents (9) (10) (11) (12) . However, the impact that these cerebrovascular alterations have on the regulation of the cerebral circulation remains to be defined. Neural activity is one of the major factors regulating CBF (13) . Thus, CBF is closely matched to the energy requirements of the brain (14) (15) (16) (17) . If a brain region is activated, blood flow to that region increases to facilitate local delivery of nutrients and to remove metabolic waste (13) . Here we report that APP and A␤ overexpression impairs the increase in neocortical CBF produced by physiological activation of the somatosensory pathway and causes a potentially-deleterious mismatch between blood flow and cerebral energy consumption.
Methods
Transgenic Mice. All transgenic lines used in these studies have been described previously (18) (19) (20) . Human APP695 variants were expressed under control of hamster prion protein sequences (18) . Tg6209 is wild-type APP whereas Tg2123 has the ''Swedish'' K670N, M671L changes; both of these arrays have a 3Ј-myc epitope tag. Tg2576 mice express Swedish mutant APP on a mixed C57BL͞6J-SJL͞J background (18, 19) , except for three congenic mice expressing the array on a C3H͞HeJ background; there was no obvious influence of genetic background differences on cerebrovascular responses or A␤ concentrations in Tg2576 mice. Transgenic line Tg1 expresses M146L mutant PS1 under the control of the same hamster prion protein cosmid insert used for the APP transgenics (20) .
Determination of CBF by Laser-Doppler Flowmetry. Mice were studied at age 2-3 mo. Techniques used for studying CBF by laser-Doppler flowmetry (CBF LDF ) were similar to those previously described (9, 10) . Mice were anesthetized with urethane (750 mg͞kg; i.p.) and chloralose (50 mg͞kg; i.p.). The trachea was intubated, and mice were artificially ventilated with an oxygen-nitrogen mixture. One femoral artery was cannulated for recording of arterial pressure and blood sampling. Rectal temperature was maintained at 37°C by using a thermostatically controlled rectal probe connected to a heating lamp. End-tidal CO 2 was monitored by a CO 2 analyzer (Capstar-100, CWE, Ardmore, PA; refs. 9 and 10). A small craniotomy (2 ϫ 2 mm) was performed to expose the whisker-barrel area of the somatosensory cortex; the dura was removed, and the site was superfused with Ringer solution (37°C; pH: 7.3-7.4; ref. 10). The laser-Doppler probe (Vasamedic, St. Paul. MN; tip diameter 0.8 mm) was mounted on a micromanipulator (Kopf) and positioned 0.5 mm above the pial surface. The right vibrissae were cut to a length of 5-10 mm and stimulated for 1 min by gently stroking them (3-4 Hz) with a cotton-tipped applicator. The CBF LDF changes produced by vibrissal stimulation in somatosensory cortex were mapped and the probe position resulting in the greatest CBF LDF increase was chosen. Vibrissal stimulation produced increases in CBF LDF that reached a stable plateau. CBF LDF increases, expressed as percentage increase, were computed as the ratio of CBF LDF at the level of the plateau and baseline CBF LDF before vibrissal stimulation (21) . Two or three vibrissal stimulation trials, separated by 10-min intervals, were averaged for each experimental condition tested. Zero values for CBF LDF were obtained after the heart was stopped by an overdose of halothane at the end of the experiment. HypercapThis paper was submitted directly (Track II) to the PNAS office.
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PNAS ͉ August 15, 2000 ͉ vol. 97 ͉ no. 17 ͉ 9735-9740 nia (pCO 2 ϭ 50-60 mmHg) was induced by introducing CO 2 in the circuit of the ventilator. At the end of the experiments, brains were removed and frozen in liquid nitrogen for subsequent measurement of A␤.
In some studies, A␤1-40, A␤1-42, or A␤40-1 (Sigma) was superfused on the cranial window at different concentrations (10 nM-10 M) in C57BL͞6J mice. Peptides were freshly solubilized in DMSO and then diluted in normal Ringer. The final DMSO concentration was Ͻ0.2%, which had no effect on cerebrovascular responses (unpublished observations). The vibrissae were stimulated after 40 min of A␤ superfusion.
Autoradiographic Determination of CBF or Cerebral Glucose Usage.
CBF was quantified by the 14 C-labeled iodoantipyrine (IAP) technique in awake APP mice [Tg2123 male (M)] (22) (23) (24) . Under halothane anesthesia, the femoral vessels were cannulated and used for arterial pressure monitoring, tracer infusion, and collection of blood samples. Wounds were treated with a 2% lidocaine ointment and sutured. Mice were allowed to recover from anesthesia for 3-4 h and placed in a loosely fitting restraining cylinder with an anterior opening to expose the face and whiskers. The right vibrissae were stroked for 1 min before IAP infusion. Whisker stimulation continued throughout the infusion period. 14 C-labeled iodoantipyrine (American Radiolabeled Chemicals, 13-20 Ci͞100 g in 0.1 ml; 1Ci ϭ 37 GBq) was infused i.v. at a constant rate for 45 sec by using an infusion pump (Harvard Apparatus, model 940). Contemporaneously timed arterial samples were collected to determine the arterial concentration time course of the tracer. At the end of the infusion, the mouse was decapitated. The brain was rapidly removed and frozen in isopentane cooled to Ϫ30°C. Coronal brain sections (20 m) were cut on a cryostat (Hacker-Bright, model OTF, Fairfield, NJ), mounted on glass slides and apposed to x-ray film together with calibrated 14 C standards) (24) . The IAP concentration in blood (nCi͞g) was determined on 20 l of blood aliquots by liquid scintillation counting. Ten days later, the film was developed and the OD of regions of interest was determined bilaterally on four adjacent sections by using a computerized image analyzer (MCID system, Imaging Research, St. Catharines, ON, Canada). OD was transformed in 14 C concentration (nCi͞g) by using the standards on the film (24) . CBF IAP (ml͞100 g͞min) was calculated using the equation described by Kety with the IAP partition coefficient set at 0.8 (24) . Physiological parameters of the mice used in CBF IAP experiments were: mean arterial pressure of APPϪ, 104 Ϯ 5; APPϩ, 99 Ϯ 8 mmHg; the pCO 2 of APPϪ, 32.5 Ϯ 1.1; APPϩ, 31.5 Ϯ 1.3 mmHg; the pO 2 of APPϪ, 94 Ϯ 3; APPϩ, 104 Ϯ 7 mmHg; the pH of APPϪ, 7.31 Ϯ 0.01; and APPϩ, 7.30 Ϯ 0.01.
Cerebral glucose usage (CGU) was determined in awake APP mice (Tg2123 M) by a modification of the 14 C-labeled 2-deoxyglucose (2-DG) method of Sokoloff (25, 26) , as described previously (21) . Mice were surgically prepared as described above for IAP. The right vibrissae were stroked for 1 min before 2-DG injection. Vibrissal stimulation continued throughout the 45 min measurement period. 14 C-labeled 2-DG (New England Nuclear; 20 Ci͞100 g in 1 ml of 0.9% NaCl) was injected i.p., and Ϸ60 l of arterial blood was collected 1, 5, 7, 10, 15, 20, 25, 35 , and 45 min later. Techniques for determination of tissue 2-DG concentration by quantitative autoradiography were identical to those described above for IAP. Plasma glucose was measured by using a glucose analyzer (Beckman). CGU (mol͞100 g͞min) was calculated from the OD of the regions of interest and the arterial time course of 2-DG using the equation developed by Sokoloff et al. (25) . Physiological parameters of the mice used in 2-DG experiments were: APPϪ: mean arterial pressure: APPϪ, 122 Ϯ 3; APPϩ, 120 Ϯ 3 mmHg; the pCO 2 of APPϪ, 34.1 Ϯ 2.0; APPϩ, 32.7 Ϯ 0.6 mmHg; the pO 2 of APPϪ, 103 Ϯ 2; APPϩ, 102 Ϯ 3 mmHg; the pH of APPϪ, 7.35 Ϯ 0.01; APPϩ, 7.36 Ϯ 0.02; the plasma glucose of APPϪ, 175 Ϯ 9; and APPϩ, 161 Ϯ 9 mg͞dl.
Determination of A␤. A␤ measurement by ELISA has been described in detail previously (27) . The right hemispheres from the mice used for CBF studies were sonicated in 70% formic acid (150 mg͞ml) and centrifuged at 100,000 ϫ g for 1 h. The formic acid extract was neutralized by a 1:20 dilution into 1 M Tris phosphate buffer (pH 8.0) and assayed by ELISA using BAN50 as capture for human transgene-specific A␤ and detection with BA27 for A␤40 and BC05 for A␤42. Femtomoles per milliliter were calculated by comparing the sample absorbance to the absorbance of known concentrations of synthetic A␤1-40 or A␤1-42 in identical solution as the samples, and these values were corrected with the wet weight of the original homogenate and are finally expressed as pmol͞gram wet weight.
Data Analysis. Data in text and figures are expressed as means Ϯ SE. Two-group comparisons were analyzed by the two-tailed t test for independent samples. Multiple comparisons were evaluated by the analysis of variance and Tukey's test. Probability values of Ͻ0.05 were considered statistically significant. 
Results
We studied the increase in somatosensory cortex blood flow produced by activation of the vibrissae in lines of transgenic mice with different concentrations of A␤ in brain. Mice were studied at an age, 2-3 mo, when amyloid deposition is not detectable in brain parenchyma or blood vessels (18, 19) . In nontransgenic mice, vibrissal stimulation increased CBF LDF in the somatosensory cortex by 30 Ϯ 1% (P Ͻ 0.001; analysis of variance). No differences in the magnitude of the hyperemic response were observed in transgene-negative mice from each of the various lines studied (Tg6209, Tg2123, and Tg2576) (P Ͼ 0.05 data not shown). Results from Tg2123 M and female (F) mice are presented separately because the transgene array in this line is located on the X chromosome. Due to random X-inactivation, only one-half the somatic cells in female mice will express the transgene; therefore, males express approximately twice the amount of APP as females. In APP mice, the magnitude of the CBF LDF increase was attenuated up to 60%. To determine whether the attenuation in the CBF response to activation was related to A␤, A␤1-40 and A␤1-42 were measured in the brains of the same mice. The magnitude of the attenuation correlated strongly with the brain concentration of A␤1-40 and A␤1-42 (Fig. 1) . In contrast to functional activation, the increase in CBF LDF produced by hypercapnia was not affected in APP transgenic mice (Table 1) . Thus, the attenuation of the hyperemic response produced by somatosensory activation is closely related to the increase in A␤ concentration in brain.
Because CBF LDF provides relative rather than absolute measurements, we also measured CBF by the quantitative IAP technique (CBF IAP ). In addition, to rule out confounding effects of anesthesia, IAP experiments were performed on awake mice. In APPϩ mice (Tg2123 M), CBF IAP was reduced in the nonactivated somatosensory cortex (Ϫ32 Ϯ 6%) and thalamus (Ϫ28 Ϯ 7%,), compared to APPϪ littermates ( Fig. 2 ; P Ͻ 0.01). However, in the nonactivated trigeminal nucleus, CBF IAP did not differ between APPϪ and APPϩ mice ( Fig. 2 ; P Ͼ 0.05). The increase in CBF IAP produced by vibrissal stimulation in somatosensory cortex was smaller in APPϩ mice (17 Ϯ 3%) than in APPϪ mice (28 Ϯ 3%; P Ͻ 0.05 from APPϩ) (Fig. 2) . In thalamus and trigeminal nucleus, however, the CBF IAP increase did not differ between APPϩ and APPϪ mice ( Fig. 2 ; P Ͼ 0.05).
To rule out the possibility that the attenuation in functional hyperemia was a consequence of reduced neural activation, we studied the effects of vibrissal stimulation on CGU in APP mice (Tg2123 M). CGU provides an accurate index of neural activity (28) . Resting CGU did not differ between APPϩ and APPϪ littermates in somatosensory areas (P Ͼ 0.05; Fig. 2 ) and in other brain regions as well (P Ͼ 0.05; data not shown). Vibrissal stimulation increased CGU in the ipsilateral trigeminal nucleus and in the contralateral thalamus and somatosensory cortex (Fig.  2) . The magnitude of the increases in CGU did not differ in APPϪ and APPϩ mice (P Ͼ 0.05) (Fig. 2) . Therefore, the reduction in the hyperemic response produced by somatosensory activation in APP mice is not associated with an attenuation of the intensity of the neural activity evoked by the stimulation.
To determine whether the impairment in functional hyperemia is related to A␤1-40 or A␤1-42, we studied mice overexpressing both APP and mutated presenilin 1 (Tg2123 F ϫ TgPS1mut). Overexpression of PS1mut in APP mice elevates brain levels of A␤1-42 (20, 29, 30) . We reasoned that, if the cerebrovascular dysfunction is mediated by A␤1-42, then the attenuation of the CBF LDF response to whisker stimulation should be substantially greater in APPϩ͞PS1mutϩ mice than in APPϩ littermates. As illustrated in Fig. 3 , PS1mut overexpression in APP mice (Tg2123 F) increased A␤1-42 by 236% above that of APPϩ͞PS1mutϪ mice, whereas A␤1-40 levels were increased by 70%. However, despite the marked increase in A␤1-42, the attenuation of the CBF LDF response to whisker stimulation in APPϩ͞PS1mutϩ mice was enhanced only by 14% (Fig. 3) . Overexpression of PS1mut alone, did not affect cerebrovascular response to vibrissal stimulation (data not shown). As illustrated in Fig. 4 , the points representing APPϩ͞PS1mutϩ mice fall within or close to the 95% confidence interval of the regression line expressing the relationship between A␤1-40 and CBF LDF . In contrast, in the regression line expressing the relationship between A␤1-42 and CBF LDF , the points repre- Mean Ϯ SE, * , P Ͻ 0.05 from normocapnia (t test); no differences in mean arterial pressure and pO2, were found between normocapnia and hypercapnia (P Ͻ 0.05, ANOVA).
senting APPϩ͞PS1mutϩ mice fall outside the 95% confidence interval (Fig. 4) . This analysis suggests that the elevation in A␤1-42 in APPϩ͞PS1mutϩ mice is out of proportion to the magnitude of the attenuation of the CBF response. It is unlikely that the lack of correspondence between A␤1-42 elevation and attenuation in CBF response is a consequence of the fact that the response is already maximally attenuated. This is because in Tg2123 M the reduction in the CBF response is greater than that observed in APPϩ͞PS1mutϩ mice (Fig. 1) . PS1mut overexpression in APP mice did not alter the increase in CBF LDF produced by hypercapnia ( Table 1) . The data presented above indicate that A␤1-40 is largely responsible for the attenuation in functional hyperemia observed in APP mice. To provide additional evidence in support of this hypothesis, we studied the cerebrovascular effects of exogenous A␤ applied topically to the neocortex of normal mice (C57BL͞6J). A␤1-40 produced concentration-dependent attenuations of resting CBF (Ϫ28% at 5 M) and of the increase in CBF LDF produced by whisker stimulation (Ϫ42% at 5 M) (Fig. 5) . In contrast, superfusion with the reverse peptide A␤40 -1 or with A␤1-42 failed to affect resting CBF LDF or the response to whisker activation (Fig. 5) . A␤1-40, 40 -1, or 1-42 did not inf luence the increase in CBF produced by hypercapnia (Table 1 ). The lack of effectiveness of A␤1-42 was not related to the fact that the peptide was dissolved in DMSO because A␤1-42 (5 M) dissolved in Ringer did not attenuate resting CBF (Ringer: 17.2 Ϯ 1.4; A␤1-42: 17.1 Ϯ 1.4 perfusion units; P Ͼ 0.05) and the increase in CBF LDF produced by somatosensory activation (Ringer: 27 Ϯ 1%; A␤1-42: 27 Ϯ 1%; P Ͼ 0.05). In mice under the same conditions of anesthesia as those used for CBF LDF studies, A␤1-40 did not attenuate CGU at the site of superfusion (superfusion 48 Ϯ 4 mol͞100 g͞min; contralateral: 49 Ϯ 5; n ϭ 5).
Discussion
We have demonstrated that mice overexpressing APP exhibit a profound defect in the CBF response to functional activation produced by somatosensory stimuli. The attenuation correlates strongly with the amount of brain A␤ and is not associated with a reduction in the degree of neural activity, as reflected by the increase in glucose usage that accompanies vibrissal stimulation. The attenuation in functional hyperemia could not be attributed to a global reduction in vascular reactivity because the increase in CBF produced by another vasodilating stimulus, hypercapnia, is preserved in APP mice. Furthermore, APP mice were studied at an age in which there is no deposition of A␤ in the brain and blood vessels, or neuronal loss (18, 19) . Therefore, it is unlikely that the reduction in the flow response is a consequence of neuronal dysfunction resulting from amyloid plaques or neurodegeneration. These findings provide evidence that APP and A␤ Fig. 2 . Effect of whisker stimulation on CBF (A) and CGU (B) in somatosensory pathways in APPϩ (CBF, n ϭ 5; CGU, n ϭ 6) and APPϪ (CBF, n ϭ 7; CGU, n ϭ 6) mice (line Tg2123 M). * , P Ͻ 0.01 (t test) from contralateral; # P Ͻ 0.05 from APPϪ. overexpression alter the balance between energy demands and blood supply in the working brain.
We found that CBF in nonactivated areas is reduced in APP mice. This suggests that resting CBF is decreased in APP mice. In the somatosensory regions examined, the reduction in CBF was present in cortex and thalamus but not in the trigeminal nucleus. CGU was similar in APP transgene positive and negative littermates suggesting that the reduction in CBF was not secondary to changes in CGU. These observations, in concert with our finding that topical superfusion of A␤1-40 reduces local CBF without altering CGU, support the hypothesis that A␤1-40 has direct vascular effects.
Two lines of evidence suggest that A␤1-40, rather than A␤1-42, is responsible for the impairment in functional hyperemia. First, despite a large increase in brain A␤1-42 in APPϩ͞PS1mutϩ mice, the hyperemic response was attenuated only slightly more than that of APPϩ͞PS1mutϪ mice. This small attenuation could be attributed entirely to the associated increase in A␤1-40. Second, superfusion with A␤1-40, but not A␤1-42, reproduced the impairment in functional hyperemia in normal mice. The reverse peptide A␤40-1 was devoid of vascular actions, attesting to the specificity of the effect of A␤1-40. In addition, studies in the isolated rat aorta have demonstrated that A␤1-40 is more vasoactive than A␤1-42 (8) . The state of aggregation or ''aging'' of the peptide may influence the biological effects of A␤1-42 (2, 31, 32) . In the present study A␤1-42 was not allowed to aggregate because it was applied to the brain immediately after being dissolved. Therefore, the possibility that A␤1-42 in a more advanced state of aggregation influences cerebrovascular reactivity cannot be ruled out. The fact that exogenous A␤ reproduces the attenuation in functional hyperemia induced by APP overexpression indicates that A␤, and not APP, is responsible for these cerebrovascular alterations.
Transgenic mice overexpressing APP also have alterations in the vasodilatation produced by pharmacological agents applied to cerebral blood vessels (9) . Furthermore, A␤ has been reported to alter vascular reactivity in isolated arteries of the rat (7, 8) . However, previous studies did not provide any insight into the physiological implications of the vascular alterations. In the present study we found that A␤, either in the brain of APP mice or topically applied to the neocortex of normal mice, impairs the augmentation of blood flow elicited by increased functional activity, one of the most critical functions of the cerebral circulation. CBF is tightly coupled to the activity, hence energy demands, of the brain. Thus, in the resting brain, regions with high activity levels, such as vestibular complex and inferior colliculus, have high blood flow rates, whereas regions with low activity, e.g., white matter tracts, have low blood flow (13, 15, 33) . Similarly, if the activity of a brain region increases, for example in the parietal cortex during somatosensory stimulation, flow to that region also increases (13, 15, 33) . The increase in CBF is thought to enhance the delivery of oxygen and substrates to the active areas, and to facilitate the removal of potentially-harmful byproducts of cerebral metabolism (13, 16) . If there is a discrepancy between energy supply and demands, critical cellular functions become impaired and, if the mismatch is persistent or severe, cellular damage occurs (34, 35) . In APP mice, the CBF response to somatosensory activation is reduced, whereas the increase in energy demands, as reflected by a rise in somatosensory cortex glucose use, is still present. Therefore, in APP mice there is an imbalance between the delivery of nutrients through blood flow and the energy requirements imposed by the activation. The observation that the activation-induced increase in CGU is not altered in APP mice, suggests that the flowmetabolism mismatch does not impair neural activity. However, it is conceivable that, over a longer period, chronic energy deprivation during activation results in brain dysfunction. Therefore, the results raise the possibility that A␤, in addition to its well-described neurotoxic effects, contributes to neuronal dysfunction also through its vascular actions. However, it remains to be established whether the vascular effects of A␤ play a role in the behavioral abnormalities that develop in APP mice (18, 19, 36) . A␤1-40 constitutes the vast majority of total A␤ secreted by cells, whereas A␤1-42 represents approximately 10% (2). However, A␤1-42 is more neurotoxic than A␤1-40 (see ref. 1 for a review). A␤1-42 is thought to activate a cytotoxic cascade characterized by microglial activation, cytokine production, inflammation and, ultimately, cellular injury (1, 2) . The finding that A␤1-40 is more vasoactive than A␤1-42 suggests that the mechanisms of the deleterious effects of these peptides might be pathogenically distinct. Whereas A␤1-42 deposition in brain tissue may initiate the cytotoxic inflammatory cascade associated with AD, A␤1-40 could exert some of its pathogenic effects by interfering with the blood supply to the brain. An interesting prediction from these studies is that Alzheimer-like pathology arising from Swedish mutant APP or trisomy 21, with elevation of both A␤1-40 and A␤1-42, might have more severe cerebrovascular dysfunction than AD resulting from other mutant APPs or mutations in PS1͞PS2 that selectively elevate A␤1-42. Irrespective of the relative roles of A␤ peptides in the mechanisms of AD, the present results provide evidence that the cerebral vascular alterations induced by A␤ alter the fine balance between energy demands, substrate delivery, and waste removal in the active brain. Such alteration, over long periods of time, may contribute to ongoing neuronal dysfunction, even before formation of amyloid plaques and related cytotoxicity.
